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OBJECTIVE—To investigate whether associations of common
genetic variants recently identiﬁed for fasting glucose or insulin
levels in nondiabetic adults are detectable in healthy children and
adolescents.
RESEARCH DESIGN AND METHODS—A total of 16 single
nucleotide polymorphisms (SNPs) associated with fasting glu-
cose were genotyped in six studies of children and adolescents of
European origin, including over 6,000 boys and girls aged 9–16
years. We performed meta-analyses to test associations of indi-
vidual SNPs and a weighted risk score of the 16 loci with fasting
glucose.
RESULTS—Nine loci were associated with glucose levels in
healthy children and adolescents, with four of these associations
reported in previous studies and ﬁve reported here for the ﬁrst
time (GLIS3, PROX1, SLC2A2, ADCY5, and CRY2). Effect sizes
were similar to those in adults, suggesting age-independent
effects of these fasting glucose loci. Children and adolescents
carrying glucose-raising alleles of G6PC2, MTNR1B, GCK, and
GLIS3 also showed reduced b-cell function, as indicated by ho-
meostasis model assessment of b-cell function. Analysis using
a weighted risk score showed an increase [b (95% CI)] in fasting
glucose level of 0.026 mmol/L (0.021–0.031) for each unit increase
in the score.
CONCLUSIONS—Novel fasting glucose loci identiﬁed in genome-
wide association studies of adults are associated with altered
fasting glucose levels in healthy children and adolescents with
effect sizes comparable to adults. In nondiabetic adults, fasting
glucose changes little over time, and our results suggest that age-
independent effects of fasting glucose loci contribute to long-term
interindividual differences in glucose levels from childhood onwards.
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Fasting glucose levels in humans are tightly regu-lated within a narrow homeostatic range; ele-vated glucose levels are a sign of reduced insulinsecretion or action and are used to test for and
diagnose type 2 diabetes. Elevated fasting glucose levels
within the normal nondiabetic range predict future risk of
diabetes (1,2) and are associated with incident cardiovas-
cular disease in nondiabetic individuals (3).
Previous studies suggested that fasting glucose levels
are heritable (4–7), with estimates from twin studies
ranging from 38 to 51%. Since 2006, a total of 16 genetic
loci have been identiﬁed to be associated with fasting
glucose levels in healthy adults (8–12). Longitudinal cohort
studies with multiple repeated measures of fasting glucose
have shown that trajectories of fasting glucose show only
modest increases over time in nondiabetic individuals (13),
suggesting that variation in fasting glucose is largely un-
affected by age-related changes in risk factors in healthy
populations and that genetic factors may be key determi-
nants of long-term interindividual differences in fasting
glucose levels. This raises the question whether the genetic
contribution to population differences in fasting glucose is
established early in life and evident in childhood.
We have previously shown associations between genetic
variants in MTNR1B, G6PC2, and SLC30A8 and fasting
glucose in children and adolescents from the European
Youth Heart Study (EYHS) (14), with additional evidence
from Weedon et al. (15) reporting that common variation
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in GCK is associated with fasting glucose in children from
the Avon Longitudinal Study of Parents and Children
(ALSPAC) cohort. In adults, the earliest identiﬁed genetic
variants appeared to inﬂuence fasting glucose levels via
effects on the glucose-sensing ability of pancreatic b-cells
(9,10,12,15–18); since then, a meta-analysis of genome-
wide association studies (GWASs) performed by the Meta-
Analyses of Glucose and Insulin-related traits Consortium
(MAGIC) identiﬁed nine additional novel fasting glucose-
associated loci exhibiting a broad range of potential func-
tionality (8). Whether these novel loci with on average smaller
effect sizes are associated with fasting glucose in children is
not known; however, individual studies are unlikely to be
powered to investigate this.
We designed this study to meta-analyze results from
over 6,000 children and adolescents participating in six
studies of European origin to systematically test the sep-
arate and joint associations of the established common
genetic variants associated with glucose-related traits in
adults. To test differences by age, we compare individual
and joint single nucleotide polymorphism (SNP) effect sizes
obtained in our meta-analysis to those reported in adults.
RESEARCH DESIGN AND METHODS
Participants. Characteristics of children and adolescents participating in the
six studies included in this meta-analysis are provided in Table 1. We included
over 6,000 children and adolescents from European (ALSPAC, Gene-Diet
Attica Investigation on Childhood Obesity [GENDAI], French case subjects
[obese], French control subjects, and EYHS) and Australian (Raine) studies.
Children and adolescents of European descent without diagnosed diabetes and
with fasting glucose levels ,7 mmol/L were eligible for this study. Detailed
study descriptions, including sampling methods, additional study-speciﬁc ex-
clusions, and the number of children and/or adolescents contributed by each
study are included in Supplementary Data (Supplementary Table 1).
Measurements. Glucose concentration was measured using commercially
available enzymatic assays after an overnight fast; full details of the method
used by each study are provided in Supplementary Table 1. Fasting insulin
concentration was measured using immunoassays (Supplementary Table 1).
The homeostasis model assessment (HOMA) was used to estimate insulin re-
sistance {HOMA-IR = [fasting glucose (mmol/L) 3 insulin (mU/mL)/22.5]} and
b-cell function {HOMA-B = [insulin (mU/mL) 3 20]/[glucose (mmol/L) 2 3.5]}
(19), both of which have been validated as surrogate markers in healthy children
(20). BMI was calculated as weight/height2; exact details of height and weight
measurements differed by cohort and are described in the Supplementary Data.
Genotyping, imputation, and quality control. Individual studies either
performed de novo genotyping of selected SNPs or provided “in silico” results
based on GWAS data, as detailed in Supplementary Table 1. EYHS and
GENDAI provided de novo genotyping results; French case and control sub-
jects, Raine, and ALSPAC studies provided in silico data. Studies used slightly
different criteria to exclude low-quality samples and SNPs before imputation;
call rates for SNPs or proxies included in this study were all .95%. Hardy-
Weinberg equilibrium test P values were . 0.05 for de novo and . 0.005 for in
silico genotypes. Imputation of additional autosomal SNPs in the GWASs was
performed using either MACH or IMPUTE computer programs from the
HapMap CEU [Centre d’Etude du Polymorphisme Humain (Utah residents
with ancestry from northern and western Europe)] reference panel (21,22).
Full details on quality control and other ﬁlters applied to SNPs, and samples
are provided in Supplementary Table 1, including information on genotyped
and imputed variants and proxies.
Statistical analysis
Study-speciﬁc analyses. In each study, effect alleles were deﬁned as the
glucose or insulin-raising allele for each SNP according to results from the
recent GWAS of adults (8). Study-speciﬁc analyses were performed using
linear regression, assuming additive genetic effects and adjusting for age, sex,
and BMI according to a prespeciﬁed standard analysis plan. Untransformed
fasting glucose and natural log-transformed fasting insulin, HOMA-B, and
HOMA-IR were used as outcomes as the latter three variables were not nor-
mally distributed. Additional study-speciﬁc covariates were included in re-
gression models for EYHS (country, laboratory) and Raine (adjustment for
ethnic stratiﬁcation by principle components analysis).
Meta-analysis. We combined results across studies by random effects meta-
analysis methods using the metan command in Stata 10.1 and DerSimonian-Laird T
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approach (23). We investigated determinants of heterogeneity across studies by
meta-regression using the metareg command and by calculation of I2, which is
deﬁned as the percentage of the total variation across studies due to hetero-
geneity between studies. Effect alleles of proxy SNPs were coded according to
the effect allele frequency of the lead SNP. Highest probability (“best guess”)
genotypes were used for analysis of imputed SNPs.
Comparison of effect sizes between adults and children/adolescents.
We compared individual SNP effect sizes for fasting glucose from our meta-
analysis of children and adolescents to those obtained in replication studies
included in the recent MAGIC GWAS of nondiabetic adults (8) using a Cochran
Q test of heterogeneity and by calculating a CI around the difference of effect
size between adults and children.
Score analysis. We used data from the EYHS cohort to compute a weighted
risk score to assess the combined associations of all 16 fasting glucose risk alleles
on glucose levels. The risk score is calculated using the following equation:
sj ¼ ∑
16
i¼1
wigij=∑
16
i¼1
wi
where sj is the score for individual j, gij is the number of risk alleles (0, 1, 2, or
dosage of the risk allele) for SNP i carried by individual j, andwi is the effect size
in children for SNP i. The denominator is the sum (over all SNPs) of effect sizes.
A total of 1,782 individuals with complete genotype information contributed
data to the score analysis; the mean BMI for the 9- to 11-year-old and 14- to 16-
year-old age-groups in these EYHS participants was 17.4 and 20.7 kg/m2, re-
spectively. Linear regression assuming an additive effect of the score was used
to test the association with fasting glucose levels (mmol/L) adjusting for age,
BMI, sex, country, and the laboratory in which samples were analyzed. To
graphically plot fasting glucose levels by values of the genetic score, we cat-
egorized individuals on the basis of their genetic score into 10 groups with
values of #11, .11–12.5, .12.5–14, .14–15.5, .15.5–17, .17–18.5, .18.5–20,
.20–21.5, .21.5–23, and .23.
Comparison of the effect of the genetic score on fasting glucose between
adults and children used data from the EYHS for children and data from the
Framingham Heart Study for adults, which was the largest of four cohorts used
by the MAGIC investigators to analyze the genetic score (8).
For children and adolescents, the weights for the weighted risk score were
calculated using the combined effect size from the meta-analysis of all six
children and adolescent studies. For adults, the weights were calculated using
effect sizes from the replication cohorts in the adult meta-analysis. Sensitivity
analyses were performed for the weighted score in children using adult weights
to avoid inﬂation of type 1 error, whichmay occur if weights from the derivation
study are used to test the effect of the genetic score in the same study.
RESULTS
Meta-analysis of results for the 16 SNPs in or near fasting
glucose loci in over 6,000 children and adolescents (Fig. 1)
showed associations with fasting glucose levels not pre-
viously demonstrated in children or adolescents for ADCY5
(rs11708067), CRY2 (rs11605924), GLIS3 (rs7034200),
PROX1 (rs340874), and SLC2A2 (rs11920090), in addition
to conﬁrming associations for variants in or near G6PC2
(rs560887), MTNR1B (rs10830963), SLC30A8 (rs13266624),
and GCK (rs4607517). All effect sizes were directionally
consistent with those observed in the MAGIC GWASs of
adults, with the exception of TCF7L2, where there was a
notable difference in effect size between adults and children/
adolescents.
Variants inDGKB (rs2191349), GCKR (rs780094), TCF7L2
(rs7903146), ADRA2A (rs10885122), MADD (rs7944584),
FADS1 (rs174550), and C2CD4B (rs11071657) did not show
signiﬁcant associations with fasting glucose in this study.
In previous meta-analyses of adults, glucose-raising
alleles of the fasting glucose variants in or near G6PC2,
MTNR1B, GCK, DGKB, ADCY5, FADS1, GLIS3, C2CD4B,
SLC30A8, and TCF7L2 were also strongly associated with
lower b-cell function estimated by HOMA-B. We observed
reduced levels (b-coefﬁcient [95% CI]) of HOMA-B for
children and adolescents carrying glucose-raising alleles in
or near GLIS3 (20.023 [20.040 to 20.006], P = 0.007) with
borderline signiﬁcant associations for ADCY5 (20.019
[0.0002 to20.038], P = 0.05) and PROX1 (20.016 [20.033 to
0.001], P = 0.067). We conﬁrm our previously reported
associations for HOMA-B (14) of G6PC2 (20.074 [20.103
to 20.046], P = 4.04 3 1027), MTNR1B (rs10830963; 20.038
[20.065 to20.011], P = 0.006), and GCK (20.047 [20.067 to
20.028], P = 2.21 3 1026) in this much larger meta-analysis
sample; associations for all other loci had P values . 0.13.
The MAGIC study in adults reported a novel association
between a variant upstream of IGF1 and fasting insulin/
HOMA-IR, as well as conﬁrming an association between
rs780094 in GCKR with both of these traits. We observed no
associations between any of the variants investigated in this
study and fasting insulin or HOMA-IR in children or ado-
lescents (all P values . 0.12). In addition, the associations
for the two insulin/HOMA-IR loci were shown to be of much
smaller size for GCKR in comparison with the adult study
and have inconsistent directions across studies for IGF1.
The weighted risk score including all variants in-
vestigated for association with fasting glucose in the cur-
rent study followed a normal distribution, with a mean
score (range) of 17.4 (7.2–27.5). Fasting glucose levels in-
creased by 0.026 mmol/L (0.021–0.031) (P = 5.6 3 10222)
for each unit increase in the score (Fig. 2). Comparison of
children and adolescents at low (score #12) versus high
(score $23) genetic susceptibility showed a difference of
0.25 mmol/L between these groups.
Effect sizes for fasting glucose associations in children,
adolescents, and adults appeared to be similar for all loci
with the exception of DGKB, GCKR, and TCF7L2, which
showed smaller point estimates in children. Effect sizes for
ADRA2A and SLC2A2 also suggested heterogeneity between
adults, adolescents, and children, but these differences
were not statistically signiﬁcant (Fig. 1 and Supplementary
Table 3).
Comparison of results for the weighted genetic risk
score in children and adolescents with the same risk score
in adults on the basis of the Framingham Heart Study
showed a difference (mean [95% CI]) of 0.34 mmol/L (0.25–
0.43) in fasting glucose between adults with a score of #12
and those with a score $23 (8) compared with children
and adolescents who showed a difference of 0.25 mmol/L
(0.15–0.35) for the same groups; this mean difference was
not signiﬁcantly different between adults and children (P =
0.19). There was also no signiﬁcant difference between the
genetic scores if the weights used in the children and ad-
olescent analysis were calculated using replication effect
sizes from the MAGIC GWAS in adults.
The MAGIC study of adults used data from replication
cohorts to investigate the proportion of variance in fasting
glucose explained by the 14 fasting glucose–associated
loci with replication data (all fasting glucose loci except
for those on TCF7L2 and SLC30A8) and found an R2 value
ranging from 3.2 to 4.4% in the six replication studies used
in their analysis. In the current study, the 14 fasting glucose–
associated loci investigated in the MAGIC study of adults
had an R2 value of 4.3% (5.1% including TCF7L2 and
SLC30A8) in the EYHS study sample, consistent with the
estimates from adult study samples.
We observed little heterogeneity for fasting glucose
associations between studies (Supplementary Table 2),
with the exception of rs10830963 in MTNR1B and
rs4607517 in GCK, which displayed an appreciable level of
heterogeneity visible in forest plots and indicated by
I2 values of 72.4 and 30.3%, respectively. Meta-regression
analyses showed that differences in mean age between
studies explained the majority of the heterogeneity in the
analysis for MTNR1B. In studies where the mean age of
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children was ,12 years, the association between MTNR1B
and fasting glucose was 0.040 (0.018–0.062) (b [per allele]
[95% CI]), whereas in children and adolescents .12 years
of age, the association was 0.106 (0.067–0.146).
None of the factors considered in the meta-regression
(age, fasting glucose levels, BMI, proportion of boys in
the study sample) explained an appreciable amount of
heterogeneity observed for GCK, with only 5.5% of the
between-study variance explained.
DISCUSSION
Novel loci recently identiﬁed to be associated with fasting
glucose in adults have an important contribution to differ-
ences in fasting glucose levels from an early age. Using data
FIG. 1. Effects of fasting glucose–associated variants in children, adolescents, and adults (in order of decreasing adult effect sizes).
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from over 6,000 children and adolescents, we show that
variants identiﬁed by their association with fasting glucose
in adults are associated with fasting glucose levels in chil-
dren and adolescents with substantial additive effects. As in
studies of adults, associations of variants with fasting glu-
cose in children and adolescents appear to be mediated via
reduced b-cell function rather than insulin sensitivity, with
associations being independent of obesity levels.
Effect sizes in adults, adolescents, and children did not
differ in magnitude for the majority of glucose variants,
suggesting that genetically determined population differ-
ences in fasting glucose are not only present at an early
age, but are maintained and constant over time.
The reason for effect estimates of ADRA2A, DGKB,
GCKR, and TCF7L2 being somewhat smaller in children
and adolescents is unclear. It is possible that associations
of these variants with glucose increase with age. However,
longitudinal analyses of repeated measures of fasting glucose
in nondiabetic adults do not provide evidence to support
this, as reported in a recent article that found no differences
in the effect sizes of these variants over time (24).
Determinants of fasting glucose trajectories in non-
diabetic individuals. The results of our meta-analysis of
fasting glucose levels in children and adolescents and our
comparison with effect sizes in adults indirectly support
previous studies investigating fasting glucose trajectories
over time in nondiabetic individuals. Trajectories of fasting
glucose in nondiabetic individuals show only modest
increases over time (13), suggesting that age-related
changes in risk factors have little inﬂuence on fasting
glucose levels in these individuals, and similar effect sizes
in children, adolescents, and adults for the majority of
established fasting glucose loci also point toward the
associations of fasting glucose loci being age independent,
a property that has not been previously reported. This
study supports a model in which genetic variants have an
important contribution to fasting glucose levels from an
early age with differences in the normal fasting glucose
range between individuals being partly determined by the
constellation of variants inherited, with each person hav-
ing a speciﬁc fasting glucose “set point” that results from
the combined effects of multiple fasting glucose loci be-
having in an additive manner. Although age-related risk
factors (e.g., BMI) contribute to variance in fasting glucose
at a cross-sectional level, because of the time-independency
displayed by fasting glucose loci and the lack of effect of
age-related risk factor changes on fasting glucose levels,
genetic population differences in fasting glucose are main-
tained long term over the course of a lifetime.
Investigation of heterogeneity. Our meta-regression
analyses suggested that the between-study heterogeneity
observed for the MTNR1B SNP is largely explained by
differences in the age distribution between these studies of
children and adolescents. This result is consistent with our
previous result that the inﬂuence of MTNR1B on glucose
levels shows interaction with pubertal stage (14), possibly
resulting from the transient period of insulin resistance
that occurs during puberty (25) and indicating the effects
of the MTNR1B variant may be greater in the context of
greater insulin secretory demand. Importantly, the range
of effect sizes observed at various stages of puberty is
consistent with the effect size observed in adults.
It has not yet been investigated whether effects of
MTNR1B are also more pronounced in risk allele–carrying
adults exposed to chronically increased secretory demand
and at higher risk for type 2 diabetes; for example, in the
context of obesity and insulin resistance. However, the
current data suggest that at least in children and adoles-
cents, the effect of MTNR1B does not differ by BMI, with
both meta-regression analysis and visual inspection of ef-
fect sizes suggesting no difference in effect size in studies
of children and adolescents with different mean BMI.
FIG. 2. Mean fasting glucose (95% CI) by categories of the genetic fasting glucose risk score in 822 boys and 960 girls of EYHS.
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Strengths and limitations. This is the ﬁrst study to
demonstrate that the majority of novel fasting glucose loci
identiﬁed in GWASs of adults are detectable in childhood
and with effect sizes comparable to those reported in
replication studies of adults. We used a diverse selection of
study samples including “hypernormal” control children in
addition to obese case subjects increasing the generaliz-
ability of results and underlining the fact that associations
of the established fasting glucose loci are independent of
obesity levels. Previous studies of children and adolescents
investigating fasting glucose loci were based on relatively
small sample sizes. Single studies are mostly underpowered
to detect associations for all but the earliest reported GWAS
variants displaying the largest effect sizes, also demon-
strated by individual study results included in our meta-
analysis. In the current study, we have overcome the
problem of false-negative replication results by meta-
analyzing a total of six studies including .6,000 children
and adolescents, constituting the largest study of fasting
glucose–associated loci in children and adolescents to date.
The original MAGIC GWASs showed associations with
b-cell function, as measured by HOMA-B, for at least 10 of
the 16 fasting glucose variants (8), and subsequent more
detailed physiological characterization conﬁrmed defects
in insulin processing and/or insulin secretion for fasting
glucose, raising alleles in or near TCF7L2, SCL30A8,
C2CD4B, MTNR1B, GCK, FADS1, DGKB, and PROX1
(26). The fasting glucose-raising allele of MADD was
associated with abnormal insulin processing, with no asso-
ciation with insulin secretion, whereas the fasting glucose-
raising allele of rs560887 in G6PC2 was associated with
greater insulin secretion (26). In the current study, we
show inverse associations of fasting glucose-raising alleles
of G6PC2, MTNR1B, GCK, and GLIS3 with HOMA-B (and
potentially weaker associations for ADCY5 and PROX1),
consistent with HOMA-B results in adults. Being restricted
to investigation of a surrogate measure based on fasting
glucose and insulin is a limitation of our study. More de-
tailed characterization of b-cell function would be required
to distinguish effects on insulin secretion from HOMA-B
associations that simply exist by virtue of each variant’s
fasting glucose link, as potentially the case for ADCY5 and
GLIS3, which showed no associations with insulin pro-
cessing, secretion, or sensitivity in adults (26). However,
epidemiological measures of b-cell function or insulin
secretion are invasive and require regular blood draws
during an oral glucose tolerance test, not commonly per-
formed in studies of children and adolescents.
An additional limitation is that the use of proxies or
imputed SNPs for some of the variants may have lead to
diluted effects, and, as such, the lack of association ob-
served for some of the variants in this study may be due to
potential measurement error or nondifferential mis-
classiﬁcation of imputed SNPs.
Public health implications. The ﬁnding that the majority
of fasting glucose loci have comparable effect sizes in
adolescents, children, and adults demonstrates that ge-
netically susceptible individuals are exposed to higher
levels of glucose and their detrimental effects on the vas-
culature from an early age and raises the question about
the clinical relevance of long-term small elevations in
fasting glucose levels in normoglycemic individuals. Stable
fasting hyperglycemia is observed in individuals with GCK
maturity-onset diabetes of the young (MODY), a mono-
genic form of diabetes caused by mutations in the GCK
gene, and is maintained over the course of a lifetime (27),
with many of these individuals showing no symptoms,
suggesting that stable mild fasting hyperglycemia may not
in itself be detrimental. However, differences in fasting
glucose levels between extremes of the fasting glucose
genetic susceptibility show a substantial effect size given
the narrow physiological range of fasting glucose, which is
similar to that seen in adults if one considers the different
fasting glucose SDs in children, adolescents, and adults
(0.35–0.53 mmol/L in the included studies of children and
adolescents and 0.43–1.4 mmol/L in nondiabetic adults
included in fasting glucose GWASs) (8). Fasting glucose
levels within the normal range are associated with an in-
crease in the risk of future type 2 diabetes (1,2), with
a .50% increased risk estimated for the fasting glucose
difference seen between extremes of the fasting glucose
score in adults (8). For cardiovascular complications,
a recent large meta-analysis suggested that elevations of
fasting glucose,7 mmol/L in nondiabetic individuals carry
a modestly elevated risk for coronary heart disease, with
hazard ratios (95% CI) of 1.17 (1.08–1.26) and 1.11 (1.04–
1.18) when comparing adults at levels of 6.1–7.0 and 5.6–
6.1 mmol/L, respectively, to the reference group with low
levels of 3.9–5.6 mmol/L (3). The degree to which early
genetic differences in fasting glucose that remain stable
throughout life translate into type 2 diabetes or its car-
diovascular complications remains to be quantiﬁed. How-
ever, the availability of multiple SNPs associated with
fasting glucose will allow assessment of the causal nature
of associations between this trait with type 2 diabetes and
cardiovascular disease using the Mendelian randomization
approach.
In conclusion, novel fasting glucose loci identiﬁed in
studies of adults are associated with fasting glucose levels
in healthy children and adolescents with effect sizes
comparable to adults for individual and combined SNP
associations. In nondiabetic individuals, fasting glucose
changes little over time, and our results suggest that age-
independent associations of fasting glucose loci contribute
to long-term interindividual differences in glucose levels
from childhood onward. The mechanisms through which
individuals that are genetically susceptible to higher fast-
ing glucose throughout life are at increased risk for type 2
diabetes and the potentially associated risk of cardiovas-
cular complications remain to be investigated.
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